European Psychiatry
April 1, 2021
B. Van der Kolk
Introduction Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Previous research has led to the designation of 3,4-methylenedioxymethamphetamine (MDMA) as a Breakthrough Therapy for treatment of post-traumatic stress disorder (PTSD) when administered as an adjunct to psychotherapy....
European Psychiatry
April 1, 2021
Pushpendra Kumar Jain, Varchasvi Mudgal, Ujwal Sardesai et al.
Introduction Dissociative identity disorder is a quite popular psychiatric diagnosis in general public but in actuality has a very low prevalence rate. Dissociative identity disorders are characterized by disruption of identity characterized by two or more distinct personality states with its own memories, behaviour, and preferences. Objectives Authors present a case report about a patient of...
European Psychiatry
April 1, 2021
Paweł Holas
Introduction Adjustment disorder (AD) is described as a maladaptive reaction to an identifiable psychosocial stressor/s that usually emerges within a month after the onset of the stressor. With all uncertainty, fears and disorientation, it’s no surprise that many people have developed an AD linked to the sudden changes brought about by COVID-19, such as threat to life, imposed restrictions, and...
European Psychiatry
April 1, 2021
M. Trigo
Introduction Depression is one of the most prevalent mental illnesses, leading to important personal distress and economic consequences. Treatment is long, often involving psychotherapy and pharmacological treatment, and relapses are frequent. Used mostly for treatment of mood disorders and alcohol dependence, drugs such as lysergic acid diethylamide (LSD) were studied in the 1950’s and showed...
European Psychiatry
August 5, 2019
Thomas M. Kelley, William F. Pettit, Jack Pransky et al.
6 citations
This theoretical article revives a classical bridging construct, canalization, to describe a new model of a general factor of psychopathology. To achieve this, we have distinguished between two types of plasticity, an early one that we call 'TEMP' for 'Temperature or Entropy Mediated Plasticity', and another, we call 'canalization', which is close to Hebbian plasticity. These two forms of...
European Psychiatry
April 1, 2017
Amira Trabsa, E. Monteagudo, D.d. Mariona et al.
2 citations
Introduction Although psychoactive substances has a long history in recreational settings, research on its composition has focused only on tablets, crystal and powder, even though new formulation for new psychoactive substances are readily available for users. Objectives To describe the presence of psychoactive substances and its characteristics in new formulations which had not previously been...
European Psychiatry
April 1, 2017
Lucie Bartova, A. Weidenauer, M. Dold et al.
IntroductionTreatment resistant depression (TRD) affecting approximately 10–30% of all depressed patients often remains misdiagnosed and undertreated, leading to a higher risk of relapse and suicide. Electroconvulsive therapy (ECT) and sub-anesthetic ketamine have repeatedly shown to be effective in the TRD population. Administering ketamine as an anesthetic component to augment antidepressant...
European Psychiatry
April 1, 2017
A. Oda
BackgroundWith the rapid and intensive spread of marihuana abuse among youth, Japanese society is focusing on law enforcement against drug abusers. In 2016, a mass killing allegedly committed by a marihuana abuser was reported in Japan.ObjectivesTo consider that common recognition of the diverse process and potential risks of cannabis psychosis should be shared among psychiatrists.AimsElicit...
European Psychiatry
April 1, 2017
M. Preve, S. Casigliani, L. Tognola et al.
IntroductionNovel psychoactive drugs (NPS) have rapidly increase in the last years in the drug market as a recreational use. A new group of toxic phenethylamine derivates named NBOMe of 2 C class present have emerged recently, are frequently bought using the internet and have similar effects to other hallucinogenic drugs; however, they may pose larger risks, due to the limited knowledge about...
European Psychiatry
April 1, 2017
E. Alisaleh, S. Ghahari
ObjectiveThe main objective of the present study is to investigate effectiveness of mindfulness-based stress reduction in anxiety and depression in patients with multiple sclerosis.MethodsThis study is in kind of semi-experimental research in form of pretest–posttest pattern with control group. Statistical population of the study consists of all patients with multiple sclerosis referred to Iran...
European Psychiatry
March 1, 2016
Laura Orsolini, Alessandro Valchera, Duccio Papanti et al.
3 citations
Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, including cannabis, MDMA (methylenedioxymethamphetamine), psilocybin, mescaline and other psychostimulants....
European Psychiatry
March 1, 2016
Inmaculada Peñuelas‐calvo, J. Sevilla Llewellyn-Jones, Aditya Sareen et al.
1 citation
Introduction Due to constant flow of people in and out of Europe several drugs are now days appearing in European markets that were previously unknown. There is a need to gain awareness and knowledge about these new substances and to recognize their use and learn about their effects and management. Aims/objectives Ayahuascais commonly called yagé is a traditional spiritual medicine in...
European Psychiatry
March 1, 2016
Arnt Schellekens, Toon Van Oosteren, Thomas Knuijver et al.
1 citation
Background The use of the hallucinogen ibogaine as an anti-addiction agent has been described in several case reports, dating back to the eighties. The anti-addiction properties of ibogaine have been confirmed in a large body of animal work. Ibogaine has been shown to be effective in reducing withdrawal severity and substance use for a variety of substances, including cocaine and opiates....
European Psychiatry
March 1, 2016
Á. Palma Conesa, L. Galindo Guarín, M. Grifell Guàrdia et al.
Introduction New psychoactive substances (NPS) are substances that have recently appeared on the market and are not under international control. NPS use is experiencing an unprecedented increase. DiPT, 4-HO-DiPT and 4-AcO-DiPT are new psychoactive tryptamines and their effects may differ from those of other psychoactive tryptamines. Objective To explore the presence of DiPT, 4-HO-DiPT and...
European Psychiatry
March 1, 2016
M. Mithoefer
IntroductionTwo serotonin reuptake inhibitors (SSRIs) have received FDA indication for treatment of PTSD, however the effectiveness of pharmacotherapy for PTSD is limited. Psychotherapy, including several well established evidence based methods, is the mainstay of PTSD treatment. Despite advances in this area, a significant percentage of PTSD patients are refractory to existing treatments....
European Psychiatry
March 1, 2016
I. Ezquiaga, M. Grifell, Liliana Galindo et al.
IntroductionNovel psychoactive substances (NPS) use is progressively increasing year on year. A new group of phenethylamines sold as legal stimulants and hallucinogens is being reported increasingly since 2012. Within this group, 25I-NBOMe is an outstanding substance with powerful effects and high affinity with the serotonin 2a (5HT2a) receptor. Several toxicity cases have been reported so...
European Psychiatry
March 1, 2016
I. Hamilton, P. Galdas, H. Essex
IntroductionDespite recent findings pointing toward cannabis psychosis as one area where gender differences may exist, there has been a widespread lack of attention paid to gender as a determinant of health in both psychiatric services and within the field of addiction.ObjectivesTo explore gender differences in treatment presentations for people with cannabis psychosis.AimsTo use national data...
European Psychiatry
November 1, 2015
L. Sala, C. Vindreau, S. Sweerts et al.
Les approches centrées sur l’autorégulation ainsi que sur l’acceptation des émotions et des sensations désagréables inspirées des programme MBSR et MBCT, représentent une voie intéressante dans la prise en charge des troubles du comportement alimentaire dans lesquels le contrôle et l’évitement sont au premier plan. Ces programmes permettent de travailler les aspects obsessionnels (comme les...
European Psychiatry
March 1, 2015
Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann et al.
20 citations
Social cognition is a crucial factor influencing development, progress, and treatment of psychiatric disorders. However, social cognition skills are insufficiently targeted by current treatment approaches. In particular, patients suffering from depression show an increased negative reaction to social exclusion and deficits in empathy. The 5HT-1A/2A receptor agonist psilocybin has previously...
European Psychiatry
March 1, 2015
D. Nutt
3 citations
Cortical 5HT2A receptors are largely expressed in layer 5 pyramidal neurons and appear to play a pivotal role in brain function in that they gate top-down descending inputs to local cortical microcircuits. There is evidence that they may play a role in depression in that the number of these receptors is increased in some people with depression and the augmenting action of atypical...
European Psychiatry
March 1, 2015
Filip Španiel, Jaroslav Tintěra, Jan Rydlo et al.
1 citation
In this study we sought to explore patterns of neural activity related to the self/other-agency judgment in patients with first-episode schizophrenia spectrum disorders (FES) and healthy controls (HC). Thirty-five FES patients and 35 age-, gender- and education-matched healthy controls. A task-related functional connectivity analysis with the use of independent component analysis (ICA). ICA...
European Psychiatry
March 1, 2015
L. Orsolini, G. Papanti, F. Professor Schifano
Due to the growing demand for alternatives to arylcyclohexylamine-type substances, a new dissociative and hallucinogenic drug, Methoxphenidine (2-MXP; (±)-1-[1-(2-methoxyphenyl)-2-phenylethyl] piperidine; 2-Meo-diphenidine) has been recently appeared in the drug market. Very little information is still available in the scientific literature on this new compound. Recently, it was identified in...
European Psychiatry
November 1, 2013
L. Sala, D. Rambaud, B. Aubriot
Nous avons mis en place dans notre CMP de secteur adulte, des protocoles de Mindfulness-Based Cognitive Therapy (MBCT) spécifiquement adaptés à des patients souffrant de phobie sociale. L’objectif de cette étude pilote était d’examiner l’efficacité du développement de MBCT à des patients souffrant de phobie sociale. Trente patients ont participé à ce jour à cette étude. Vingt-quatre personnes...
European Psychiatry
March 1, 2011
H. Murphy, M. Lahtinen
NICE guidelines indicate one in five people will suffer from depression at some point in their lives with relapse rates of 50–80% in those who have experienced one or more episodes of depression (National Institute for Health and Clinical Excellence [NICE], 2007). By 2020, depression is predicted to be the second largest cause of death or disability and consequently there is a need to explore...
European Psychiatry
March 1, 2011
E.C. Sundin, Edo Shonin, William van Gordon et al.
Mindfulness meditation has been practiced in the Eastern world for more than 25 centuries but only recently it has become popular in the West. Today, therapeutic interventions such as ‘Mindfulness Based Stress Reduction’ are used within health services throughout Europe as a means of improving patient wellbeing. Whilst these interventions have proved successful in reducing stress and depression...